Novo is a show-me story; a turnaround is possible but requires time due to competitive pressure in the injectable market.

And I think while Novo has a good oral wgoi drug that is launching well to be fair and is still one of their bright spots uh the question is in five years is Lily's foundo going to be at or above but most importantly as we've talked about the injectable market is still going to be 65 or 75% of the overall market and Lily's got not only tepatide but you're going to hear about in a month or two the triple G which I think a lot of people including in Silicon Valley are compounding a bit the triple G and also amalin which you're going to hear about which has very high efficacy and not a lot of side effect.

I think Novo still remains a show me story whether or not they can turn this around. I think there will be a turnaround story over a few years, but it's going to take time.